Understanding Mounjaro-Related Hair Loss

The connection between Mounjaro (tirzepatide) and hair loss has gained attention since the medication’s UK approval by the MHRA in November 2023 for weight management, with NHS rollout beginning in June 2025. While not everyone experiences this side effect, understanding the mechanisms and timeline helps patients make informed decisions and reduces unnecessary anxiety about this common but transient concern.

The good news is that this represents a manageable, well-understood phenomenon with clear prevention and treatment pathways, and it rarely requires stopping this important medication that delivers substantial metabolic and cardiovascular benefits.

Clinical Evidence: How Common Is Hair Loss?

The official UK Patient Information Leaflet classifies hair loss (alopecia) as a common side effect that may affect up to 1 in 10 people (10%) using Mounjaro for weight management. This designation emerged from the SURMOUNT clinical trials, where 4.9-5.7% of participants taking 5-15mg doses experienced hair loss compared to just 0.9% receiving placebo.

A landmark study presented at the European Academy of Dermatology and Venereology Congress in September 2025 analysed 547,993 GLP-1 receptor agonist users over ten years. They found a 76% increased risk of telogen effluvium at 12 months of use, with risk increasing progressively over time.

Why Does Mounjaro Cause Hair Loss?

Mounjaro does not directly damage hair follicles or cause follicular toxicity. Rather, hair loss occurs as an indirect consequence of rapid weight loss triggering a condition called telogen effluvium—a form of temporary, reversible hair shedding that affects the entire scalp diffusely.

The Hair Growth Cycle

Understanding the normal hair cycle is essential:

• Anagen phase (active growth): Lasts 2-7 years, accounts for 85-90% of scalp hairs
• Catagen phase (transition): Lasts 2-3 weeks
• Telogen phase (resting): Lasts 2-4 months, accounts for 10-15% of hairs

When the body experiences significant physiological stress—such as rapid weight loss—up to 30-70% of follicles prematurely shift into telogen phase. After the characteristic 2-4 month lag period, these resting hairs shed simultaneously, producing dramatic increases to 150-300+ hairs lost daily.

Multiple Stress Mechanisms

• Energy deficit: Hair follicles contain the fastest dividing cells in the body, making them extremely sensitive to caloric restriction
• Nutritional deficiencies: Reduced food intake makes it challenging to meet protein, iron, zinc, and vitamin requirements
• Hormonal changes: Rapid fat loss reduces oestrogen production and affects thyroid and cortisol levels
• Metabolic stress: Reactive oxygen species increase in follicles, disrupting mitochondrial function

Timeline: When to Expect Hair Loss and Recovery

Nutritional Strategies to Prevent Hair Loss

Optimising nutrition represents the most important modifiable factor for preventing and minimising Mounjaro-related hair loss.

Priority Nutrients

Essential Micronutrients

• Iron: Women need 18mg daily (8mg for men). Ferritin levels should be >40-50 ng/mL. Sources include red meat, spinach, lentils, fortified cereals
• Zinc: Adults need 8-11mg daily. Sources include oysters, red meat, poultry, seafood, eggs, nuts
• Vitamin D: Supplement with 2,000-5,000 IU daily. Optimal levels: 50-70 ng/mL
• B-vitamins: Folate (400 mcg), B12 (2.4 mcg), B6 (1.3-1.7mg) from meat, fish, eggs, whole grains
• Vitamin C: 75-90mg daily. Enhances iron absorption when consumed together
• Omega-3s: 2-3 servings of fatty fish weekly or 1,000-2,000mg EPA/DHA supplement

When to Seek Medical Advice

Schedule a Routine Appointment If:

• Hair shedding continues beyond 6 months
• No improvement after addressing nutrition and reducing stress
• Losing more than 300 hairs daily consistently
• Noticeable thinning or widening part line
• Significant psychological distress

Recommended Baseline Testing

• Complete blood count (CBC) to assess for anaemia
• Serum ferritin to measure iron storage (target >40-50 ng/mL)
• Thyroid function tests (TSH and free T4)
• Vitamin D levels
• Comprehensive metabolic panel

Treatment Options

For most cases of acute telogen effluvium lasting under 6 months, no active treatment is required—the condition resolves spontaneously. However, several evidence-based treatments exist for patients desiring active intervention.

Topical Minoxidil (Regaine)

Available over-the-counter in the UK. Apply 2% or 5% solution/foam twice daily to dry scalp. Visible results typically appear in 3-6 months. May cause initial increased shedding during weeks 2-4 (resolves by week 6).

Nutritional Supplementation

Prescription-strength supplements for confirmed deficiencies including iron, vitamin D, and medical-grade multivitamins. Working with a registered dietitian provides personalised nutrition planning.

Platelet-Rich Plasma (PRP)

Blood-derived growth factors injected into scalp. Typically requires monthly sessions for 3 months, then maintenance every 3-6 months. Safe and natural but expensive and not NHS-funded.

Low-Dose Oral Minoxidil

Once-daily dosing at 0.25-5mg. Off-label use requiring medical supervision. May be more effective than topical application for chronic cases.

Should You Continue or Stop Mounjaro?

The medical consensus is clear: generally, do not stop Mounjaro solely due to hair loss.

Why Continue Treatment

• Hair loss is temporary—resolves in 95% of cases
• Caused by weight loss, not medication toxicity
• Stopping won’t reverse current shedding (hairs already in telogen will shed regardless)
• Mounjaro provides significant metabolic and cardiovascular benefits
• No participants discontinued due to hair loss in clinical trials

When to Discuss Dose Adjustment

• Weight loss exceeds 2 pounds/week consistently
• Severe nausea prevents meeting minimum nutritional requirements
• Cannot consume adequate protein despite best efforts
• Hair loss causes severe psychological distress

Comparing Mounjaro to Other GLP-1 Medications

Hair loss associates with all GLP-1 receptor agonists to varying degrees, with risk correlating more strongly with magnitude and speed of weight loss than with the specific medication.

• Semaglutide (Ozempic/Wegovy): Highest signal with 199 reports and ROR of 2.46. Women face 2.08 times higher risk
• Tirzepatide (Mounjaro/Zepbound): 179 reports with ROR of 1.73. Gender disparity: 7.1% females vs 0.5% males
• Liraglutide (Saxenda): Moderate risk with 1.26% reporting hair loss
• Other GLP-1s: Lower reporting rates overall

The Bottom Line for UK Patients

Mounjaro-related hair loss represents a common but temporary side effect affecting up to 1 in 10 people using the medication for weight management in the UK. The condition results from rapid weight loss triggering telogen effluvium rather than direct medication toxicity, meaning it is reversible and self-limiting in the vast majority of cases.

Recovery occurs spontaneously within 6-12 months once weight stabilises and nutritional deficiencies are addressed, making patience and realistic expectations essential. Evidence-based prevention and management strategies exist and should be implemented from the start of treatment.

Most importantly, continue Mounjaro unless medically contraindicated—the metabolic and cardiovascular benefits typically far outweigh the temporary cosmetic concern of hair thinning. Understanding that hair loss reflects a well-understood physiological response to metabolic stress rather than medication harm provides crucial perspective.